A carregar...
Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab
Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5407507/ https://ncbi.nlm.nih.gov/pubmed/28473905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717695723 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|